Reduced expression of miR-564 is associated with worse prognosis in patients with osteosarcoma.
MiR-564 has been reported to be involved in the development of several types of cancers. However, its clinical significance in osteosarcoma (OS) has not been investigated. We aimed to explore the prognostic value of miR-564 in OS patients. Quantitative RT-PCR assay was used to detect the expression levels of miR-564 in OS tissues and matched normal bone tissues. The correlation between miR-564 expression and clinicopathological features was analyzed by Pearson's χ2-test. The disease-free survival and overall survival rates of OS patients were calculated by the Kaplan-Meier method. Cox regression analysis was used to assess factors related to survival. We observed that the level of miR-564 was significantly reduced in OS tissues compared with that in the paired noncancerous bone tissues (p < 0.01). In addition, low miR-564 expression was found to be closely correlated with advanced clinical stage (p = 0.000) and distant metastasis (p = 0.003). Furthermore, survival analyses showed that patients with low expression of miR-564 had a shorter overall survival (p = 0.001) and disease-free survival (p = 0.001) than those with high expression of miR-564. Finally, we showed that miR-564 was an independent poor prognostic factor for both 5-year overall survival (p = 0.001) and 5-year disease-free survival (p = 0.001) through multivariate analysis. Overall, our data for the first time suggest that downregulated miR-564 may be used as a novel prognosis predictor of OS.